Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUNAVAIL vs CYCLOBENZAPRINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
Treatment of muscle spasm associated with acute, painful musculoskeletal conditions (FDA approved),Adjunct to rest and physical therapy for relief of muscle spasm (FDA approved)
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Terminal half-life: 18–24 hours (range 8–37 hours). Clinical context: requires multiple doses to achieve steady state (5–6 days); active metabolite norcyclobenzaprine has half-life ~30 hours.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Hepatic metabolism primarily via CYP3A4, CYP1A2, and CYP2D6; also undergoes N-demethylation and glucuronidation. Active metabolites include norcyclobenzaprine.
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40% primarily as metabolites; Biliary: minimal.
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
~93% bound to albumin and alpha-1-acid glycoprotein.
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
~5 L/kg (range 3–7 L/kg). Clinical meaning: extensive tissue distribution, including central nervous system.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
Oral: 33–55% due to first-pass metabolism; lower for immediate-release compared to extended-release (same extent but slower absorption).
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
No specific dosing adjustment recommended; use caution in severe renal impairment due to potential accumulation.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Child-Pugh Class A or B: No adjustment. Child-Pugh Class C: Contraindicated due to risk of toxicity (minimal data). Use with caution in mild to moderate impairment; consider lower starting dose.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Not recommended for children under 15 years; safety and efficacy not established. For adolescents ≥15 years: same as adult dosing.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
Start with 5 mg once daily; increase slowly to a maximum of 10 mg three times daily over 2 weeks. Increased sensitivity; monitor for anticholinergic effects and sedation.
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
None
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Serotonin syndrome risk, especially with concomitant serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs),Sedation and impairment of motor skills; caution with driving or operating machinery,Anticholinergic effects (e.g., urinary retention, angle-closure glaucoma, constipation),Cardiovascular effects: tachycardia, QT prolongation, arrhythmias (especially in elderly or with pre-existing heart disease),Hepatic impairment: use with caution; reduced clearance in mild impairment, avoid in severe impairment,Withdrawal symptoms after abrupt discontinuation: dysphoria, anxiety, insomnia,Elderly patients: increased risk of falls, confusion, anticholinergic toxicity
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
Hypersensitivity to cyclobenzaprine or any component of the formulation,Concomitant use or within 14 days of MAO inhibitors (hypertensive crisis risk),Acute recovery phase after myocardial infarction,Arrhythmias, heart block, or conduction disturbances,Hyperthyroidism,Severe hepatic impairment
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
Alcohol should be avoided due to additive CNS depression. Grapefruit juice may increase cyclobenzaprine levels (though data is limited, caution is advised). High-fat meals may delay absorption but not clinically significant. No specific dietary restrictions are required.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. First trimester: Limited human data, but no structural anomalies reported. Second trimester: No specific adverse effects documented. Third trimester: Potential for neonatal withdrawal symptoms (e.g., jitteriness, respiratory depression) if used near term.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
Cyclobenzaprine is excreted into breast milk in low amounts; the M/P ratio is unknown. Due to its anticholinergic effects, there is potential for adverse effects in the nursing infant (e.g., sedation, constipation). The American Academy of Pediatrics considers it compatible with breastfeeding, but caution is advised; alternatives may be preferred.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
No specific dose adjustments are recommended during pregnancy. Pharmacokinetic parameters (e.g., clearance) are not significantly altered by pregnancy. Use the lowest effective dose for the shortest duration due to lack of safety data.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Cyclobenzaprine is structurally related to tricyclic antidepressants and shares similar anticholinergic and sedative properties. Onset of action for muscle relaxation is typically 1 hour, but maximal effect may take several days. Avoid use in patients with hyperthyroidism, cardiac disease, or those on MAOIs. Not recommended for use longer than 2-3 weeks due to lack of evidence for chronic use. Caution in elderly due to anticholinergic effects and fall risk.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol or use other CNS depressants (e.g., benzodiazepines, opioids) while taking this medication, as it may increase sedation.,Take this medication exactly as prescribed, usually 3 times a day. Do not take more or less than directed.,This medication is intended for short-term use (up to 2-3 weeks) for muscle spasm. Do not use it for longer without consulting your doctor.,If you experience dry mouth, try sucking on sugar-free candy or ice chips. If you have difficulty urinating or vision changes, contact your doctor.,Do not stop taking this medication abruptly without consulting your doctor, although withdrawal is uncommon with short-term use.
No interactions on record
"The combination of cyclobenzaprine and carbinoxamine results in additive central nervous system depression due to their shared anticholinergic and sedative properties. This can lead to excessive sedation, impaired cognitive and motor function, and increased risk of falls or accidents. Severe cases may result in respiratory depression, especially in elderly patients or those with preexisting conditions."
"Cyclobenzaprine, a centrally acting muscle relaxant with tricyclic antidepressant (TCA)-like structure, and Dezocine, an opioid partial agonist analgesic with mu-opioid receptor activity, both depress the central nervous system (CNS) and have additive serotonergic effects. Concomitant use increases the risk of excessive CNS depression, manifesting as sedation, respiratory depression, and impaired psychomotor function, as well as potential serotonin syndrome due to combined serotonergic activity. Clinically, patients may experience profound drowsiness, confusion, respiratory compromise, and in severe cases, coma or death from respiratory failure."
"Lumacaftor, a potent inducer of cytochrome P450 (CYP) 3A4, significantly reduces the systemic exposure of cyclobenzaprine, a CYP3A4 substrate. This results in decreased plasma concentrations of cyclobenzaprine, potentially leading to reduced therapeutic efficacy for muscle spasm relief. Patients may require dose adjustments or alternative therapies to maintain clinical benefit."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUNAVAIL vs CYCLOBENZAPRINE HYDROCHLORIDE, answered by our medical review team.
BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. CYCLOBENZAPRINE HYDROCHLORIDE is a Skeletal Muscle Relaxant that works by Cyclobenzaprine is a centrally acting muscle relaxant that reduces tonic somatic motor activity at the supraspinal level, primarily at the brainstem reticular formation and descending pathways. It is structurally related to tricyclic antidepressants and inhibits reuptake of norepinephrine and serotonin, but the direct relationship to its muscle relaxant effects is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUNAVAIL and CYCLOBENZAPRINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. The standard adult dose of CYCLOBENZAPRINE HYDROCHLORIDE is: Adults: 5 mg orally three times daily; may increase to 10 mg three times daily based on response. Maximum 30 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUNAVAIL and CYCLOBENZAPRINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. CYCLOBENZAPRINE HYDROCHLORIDE is classified as Category A/B. Cyclobenzaprine is classified as FDA Pregnancy Category B. Animal reproduction studies have not shown fetal risk, and there are no adequate and well-controlled studies in pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.